Decision and Details
Board of DirectorsExecution of a basic agreement for a revolving credit facility with SBI Securities Co., Ltd.
To secure a flexible and stable funding source for future funding needs associated with the Phase 3 clinical trial of CBP501 in Europe and further strengthen the company's financial base.
The impact on results for the fiscal year ending June 2027 is expected to be immaterial.
| Item | Details |
|---|---|
| Matter Covered | Execution of a basic agreement for a revolving credit facility with SBI Securities Co., Ltd. |
| Decision-Making Body | Board of Directors |
| Decision Date | 14 October 2026 |
| Implementation Date | 2 November 2026 (scheduled agreement execution date) |
| Period Covered | 2 November 2026 to 7 May 2027 (scheduled) |
| Amount | Maximum borrowing limit: ¥500 million; fixed interest rate: 3.0% (reference rate plus spread) |
| Impact on Business Performance | The impact on results for the fiscal year ending June 2027 is expected to be immaterial. |
| Reason | To secure a flexible and stable funding source for future funding needs associated with the Phase 3 clinical trial of CBP501 in Europe and further strengthen the company's financial base. |
| Related previous disclosures | The notice dated 14 October 2026 titled “Notice Regarding the Issuance of the 22nd Series Stock Acquisition Rights through a Third-Party Allotment (with Provisions for Adjustment of the Exercise Price) and the 23rd and 24th Series Stock Acquisition Rights (with Options to Adjust the Exercise Price)” |
| Future plans | The agreement is scheduled to be executed on 2 November 2026. Individual borrowings are expected to be drawn within the maximum borrowing limit, depending on the progress of the European Phase 3 trial and funding needs. The company will promptly disclose any matters requiring disclosure that arise in the future. |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because substantial funding needs are expected to arise as the European Phase 3 trial progresses, the company seeks to secure a flexible and stable funding source and strengthen its financial base while taking existing shareholders' dilution into consideration.